Detection of Aluminium-reactive T-lymphocytes in Patients With Vaccination Granulomas

Granuloma Clinical Trial

Official title: Detection of Aluminium-reactive T-lymphocytes in Patients With Vaccination Granulomas

Status Completed

Clinical Trial Summary

Vaccines and subcutanoeus immunotherapy vaccines often contains aluminium, and may induce itching granulomas at the injection site. This is usually diagnosed by patch testing. Another way of detecting metal allergy is by investigation metal-specific cells in the blood. We include participants both with and without granulomas, all have a blood test taken where we investigate if any participants have aluminium-specific cirkulation cells, and whether we can detect a difference between participants with and without granulomas.

Clinical Trial Description

Aluminium-adsorbed vaccines and subcutaneous immunotherapy may induce vaccination granulomas at injection site. Most children have concormitant aluminium contact allergy diagnosed by path testing, but in adults the allergy can rarely be detected by patch tests. An alternative to patch testing is the blood in vitro lymphocyte proliferation test (LPT), which we investigated using a well-established LPT protocol. This has previously been shown to detect and characterize metal-specific cells and was used to detect circulating aluminium-specific proliferation. The LPT test is based on a single blood sample and has mostly been used to detect drug hypersensitivity. Still, its role in detecting metal allergy is expanding, with recent studies suggesting using the test as a supplement to the patch test when only a few allergens are to be investigated. ;

Related Conditions & MeSH terms

• Aluminum Allergy
• Granuloma

• NCT number: NCT06130462
• Study type: Interventional
• Source: National Allergy Research Center, Denmark
• Status: Completed
• Phase: N/A
• Start date: September 13, 2022
• Completion date: February 20, 2023